Matches in Wikidata for { <http://www.wikidata.org/entity/Q52679360> ?p ?o ?g. }
- Q52679360 description "2018 nî lūn-bûn" @default.
- Q52679360 description "2018年の論文" @default.
- Q52679360 description "2018年学术文章" @default.
- Q52679360 description "2018年学术文章" @default.
- Q52679360 description "2018年学术文章" @default.
- Q52679360 description "2018年学术文章" @default.
- Q52679360 description "2018年学术文章" @default.
- Q52679360 description "2018年学术文章" @default.
- Q52679360 description "2018年學術文章" @default.
- Q52679360 description "2018年學術文章" @default.
- Q52679360 description "2018年學術文章" @default.
- Q52679360 description "2018年學術文章" @default.
- Q52679360 description "2018年學術文章" @default.
- Q52679360 description "2018년 논문" @default.
- Q52679360 description "article científic" @default.
- Q52679360 description "article scientific" @default.
- Q52679360 description "article scientifique" @default.
- Q52679360 description "articol științific" @default.
- Q52679360 description "articolo scientifico" @default.
- Q52679360 description "artigo científico" @default.
- Q52679360 description "artigo científico" @default.
- Q52679360 description "artigo científico" @default.
- Q52679360 description "artikel ilmiah" @default.
- Q52679360 description "artikull shkencor" @default.
- Q52679360 description "artikulong pang-agham" @default.
- Q52679360 description "artykuł naukowy" @default.
- Q52679360 description "artículo científico publicado en 2018" @default.
- Q52679360 description "artículu científicu" @default.
- Q52679360 description "bilimsel makale" @default.
- Q52679360 description "bài báo khoa học" @default.
- Q52679360 description "naučni članak" @default.
- Q52679360 description "scienca artikolo" @default.
- Q52679360 description "scientific article published on 21 February 2018" @default.
- Q52679360 description "scientific article published on 21 February 2018" @default.
- Q52679360 description "scientific article published on 21 February 2018" @default.
- Q52679360 description "teaduslik artikkel" @default.
- Q52679360 description "tieteellinen artikkeli" @default.
- Q52679360 description "tudományos cikk" @default.
- Q52679360 description "vedecký článok" @default.
- Q52679360 description "vetenskaplig artikel" @default.
- Q52679360 description "videnskabelig artikel" @default.
- Q52679360 description "vitenskapelig artikkel" @default.
- Q52679360 description "vitskapeleg artikkel" @default.
- Q52679360 description "vědecký článek" @default.
- Q52679360 description "wetenschappelijk artikel" @default.
- Q52679360 description "wissenschaftlicher Artikel" @default.
- Q52679360 description "επιστημονικό άρθρο" @default.
- Q52679360 description "мақолаи илмӣ" @default.
- Q52679360 description "наукова стаття, опублікована в лютому 2018" @default.
- Q52679360 description "научна статия" @default.
- Q52679360 description "научная статья" @default.
- Q52679360 description "научни чланак" @default.
- Q52679360 description "научни чланак" @default.
- Q52679360 description "מאמר מדעי" @default.
- Q52679360 description "مقالة علمية نشرت في 21 فبراير 2018" @default.
- Q52679360 description "২১ ফেব্রুয়ারি ২০১৮-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q52679360 description "บทความทางวิทยาศาสตร์" @default.
- Q52679360 description "სამეცნიერო სტატია" @default.
- Q52679360 name "Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study." @default.
- Q52679360 name "Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study." @default.
- Q52679360 type Item @default.
- Q52679360 label "Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study." @default.
- Q52679360 label "Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study." @default.
- Q52679360 prefLabel "Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study." @default.
- Q52679360 prefLabel "Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study." @default.
- Q52679360 P1433 Q52679360-EEED3531-442D-4B8D-971E-F3E7CED05062 @default.
- Q52679360 P1476 Q52679360-2F9749A6-79F2-4D96-95CE-281B5B8CA9EA @default.
- Q52679360 P2093 Q52679360-063209A0-30A6-4D21-95FE-FA8FFA9AE1AE @default.
- Q52679360 P2093 Q52679360-0C08FC8E-16CA-46F2-919E-31CA2518D616 @default.
- Q52679360 P2093 Q52679360-0F2D757D-8630-4E85-9956-7DF39F659C4F @default.
- Q52679360 P2093 Q52679360-113398AE-D867-43A8-B2C1-17144F2DE1F9 @default.
- Q52679360 P2093 Q52679360-1A8DAA43-CF89-4622-ADDC-F7468579F351 @default.
- Q52679360 P2093 Q52679360-4468A3FB-A494-42F5-8187-B3B4477FB8A6 @default.
- Q52679360 P2093 Q52679360-572A6AA5-977B-4A2D-8CB4-05DE9D686410 @default.
- Q52679360 P2093 Q52679360-6338CC22-AF5B-4D54-9F32-E16B7EB9EC97 @default.
- Q52679360 P2093 Q52679360-71A4AFD8-4933-4EFB-88AF-F91BA3B153D3 @default.
- Q52679360 P2093 Q52679360-73DDE15F-1CFD-47EA-B40E-414B7126CC8A @default.
- Q52679360 P2093 Q52679360-8D860409-70CB-46CF-8010-3618CA7C3879 @default.
- Q52679360 P2093 Q52679360-9F171215-31B7-4413-8754-6075063FD753 @default.
- Q52679360 P2093 Q52679360-D41E5EF7-09BC-4869-B2D5-16FC4A75E875 @default.
- Q52679360 P2093 Q52679360-EFAE9958-A938-4BCA-9EE8-51241407AA10 @default.
- Q52679360 P2093 Q52679360-F3CB39E9-6847-4994-BD0B-39945C58F140 @default.
- Q52679360 P2093 Q52679360-F5DB46B2-1788-41D0-AB33-D2356EB52A89 @default.
- Q52679360 P304 Q52679360-CF3C6491-A8F3-4679-B1A1-3C2DED47B0E5 @default.
- Q52679360 P31 Q52679360-3ACE896D-2F59-45B5-989D-E5927443014A @default.
- Q52679360 P356 Q52679360-B98AC88A-0012-49F0-B6C9-F0E351CD45C5 @default.
- Q52679360 P478 Q52679360-16799D41-A561-47F2-945C-74986E33EED9 @default.
- Q52679360 P577 Q52679360-97614198-095A-4C34-A38A-5722BD5AD0B4 @default.
- Q52679360 P698 Q52679360-6C936C9E-6FFA-4B40-AEBA-84728C0EEB49 @default.
- Q52679360 P921 Q52679360-28FEB4ED-55E0-455B-B164-A127965D07CB @default.
- Q52679360 P356 J.LEUKRES.2018.02.013 @default.
- Q52679360 P698 29494928 @default.
- Q52679360 P1433 Q15716445 @default.
- Q52679360 P1476 "Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study." @default.
- Q52679360 P2093 "Ann Solterbeck" @default.
- Q52679360 P2093 "Anthony Powell" @default.
- Q52679360 P2093 "Carly Levetan" @default.
- Q52679360 P2093 "David T Yeung" @default.
- Q52679360 P2093 "Devendra Hiwase" @default.
- Q52679360 P2093 "Ian Irving" @default.